Nuveen
INDV icon

Nuveen’s Indivior Pharmaceuticals INDV Stock Holding History

Nuveen’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Sell
856,000
-74,911
-8% -$2.72M 0.01% 917
2026
Q1 		$28.4M Sell
930,911
-6,791
-0.7% -$224K 0.01% 936
2025
Q4 		$33.6M Buy
937,702
+78,057
+9% +$2.38M 0.01% 842
2025
Q3 		$20.7M Buy
859,645
+517,402
+151% +$10.8M 0.01% 1126
2025
Q2 		$5.05M Buy
342,243
+257,519
+304% +$3M ﹤0.01% 1878
2025
Q1 		$793K Sell
84,724
-8,035
-9% -$84.5K ﹤0.01% 2741
2024
Q4 		$1.19M Hold
92,759
– – ﹤0.01% 2638
2024
Q3 		$916K Hold
92,759
– – ﹤0.01% 2800
2024
Q2 		$1.45M Hold
92,759
– – ﹤0.01% 2540
2024
Q1 		$1.98M Sell
92,759
-5,741
-6% -$108K ﹤0.01% 2409
2023
Q4 		$1.49M Buy
+98,500
New +$1.75M ﹤0.01% 2549

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's INDV Position: Q2 2026 in Review

Nuveen reduced its Indivior Pharmaceuticals (INDV) stake by 8% in Q2 2026, selling an estimated $2.72M and leaving 856,000 shares worth $35.1M. The position accounts for 0.01% of the portfolio, ranked #917.

Nuveen first reported a position in INDV in Q4 2023 and has held it in 11 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Nuveen held 856,000 shares of Indivior Pharmaceuticals worth $35.1M as of Q2 2026.
  • Nuveen sold 74,911 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.72M.
  • Indivior Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #917 holding.
  • Nuveen first reported a position in Indivior Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.